CMV-TCR-T Cells for Refractory CMV Infection After HSCT

Inclusion Criteria:

1. Patients with acute leukemia (AL) or myelodysplastic syndrome (MDS) who receivehaploid allogeneic hematopoietic stem cell transplantation, pre-transplantationassessment ≤CR2;
2. Age 18-60, including boundary value, gender unlimited;
3. Refractory CMV infection occurred in the early stage of transplantation : After 2weeks of standard antiviral treatment, the CMV DNA copy number continued to be ≥1000copies/mL, and the CMV DNA copy number at the beginning of the treatment decreased by <log10 ；
4. The transplant donor's HLA-A matching is one of 2402, 0201 or 1101, and the physicalexamination is qualified;
5. ECOG ≤ 3, estimated life expectancy> 3 months;
6. Patients who voluntarily sign informed consent and are willing to comply withtreatment plans, visit arrangements, laboratory tests and other research procedures.

Exclusion Criteria:

1. Patients with active aGVHD III-IV and / or mild and severe cGVHD;
2. Have received cell therapy such as DLI, CTL, CAR-T, NK or participated in any otherclinical research on drugs and medical devices;
3. Patients who have developed CMV disease;
4. patients with organ failure:

• Heart: NYHA heart function grade IV;
• Liver: Grade C that achieves Child-Turcotte liver function grading;
• Kidney: kidney failure and uremia;
• Lung: symptoms of respiratory failure;
• Brain: a person with a disability;

5. Pregnant or lactating women;
6. The researchers found that it was unsuitable for the recipients to be enrolled.